The Food and Drug Administration of the United States may halt cancer drugs and other medicines made in China.
The federal agency of the Department of Health and Human Services has raised concerns about the studies conducted in China. It raised doubts about whether these studies can apply to patients in the United States.
It comes as the FDA is holding an advisory meeting to review the effectiveness of sintilimab used for cancer immunotherapy.